ReviewNature reviews. Cancer2015
Tumorigenesis: it takes a village.
Review in Nature reviews. Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 304 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
304 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Applications of lung cancer organoids in precision medicine: from bench to bedside.Cell communication and signaling : CCS · 2023Pooled it
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Dolphyin: a combinatorial algorithm for identifying 1-Dollo phylogenies in cancer.Algorithms for molecular biology : AMB · 2026Article
- Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives.Protein & cell · 2026Review
- Tumor ecology and the paradox of clean margins in multicentric breast cancer: an exploratory organoid-based functional study.Breast cancer research : BCR · 2026Review
- LDAcoop: Integrating non-linear population dynamics into the analysis of clonogenic growth in vitro.Molecular oncology · 2026Article
- Article
- Strength through diversity: how cancers thrive when clones cooperate.Molecular oncology · 2026Review
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- LeGO-3D: 3D imaging of lung metastases and vascularisation using light sheet fluorescence microscopy.Npj imaging · 2025Article
- Chemoselective Characterization of New Extracellular Matrix Deposition in Bioengineered Tumor Tissues.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- MMP9 shapes cell mechanics to enable collective invasion in cancer.NPJ systems biology and applications · 2025Article
- From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research.Nature methods · 2025Review
- Article
- Tumors and their microenvironments: Learning from pediatric brain pathologies.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Bayesian inference of fitness landscapes via tree-structured branching processes.Bioinformatics (Oxford, England) · 2025Article
- Review
- Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Tumor growth dynamics under adaptive therapy: a multi-scale computational approach.Theory in biosciences = Theorie in den Biowissenschaften · 2025Article
- Unjamming Transition as a Paradigm for Biomechanical Control of Cancer Metastasis.Cytoskeleton (Hoboken, N.J.) · 2025Review
244 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although it is widely accepted that most cancers exhibit some degree of intratumour heterogeneity, we are far from understanding the dynamics that operate among subpopulations within tumours. There is growing evidence that cancer cells behave as communities, and increasing attention is now being directed towards the cooperative behaviour of subclones that can influence disease progression. As expected, these interactions can add a greater layer of complexity to therapeutic interventions in heterogeneous tumours, often leading to a poor prognosis. In this Review, we highlight studies that demonstrate such interactions in cancer and postulate ways to overcome them with better-designed therapeutic strategies.
Indexed as
Identifiers
26156638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.